Published in Acta Obstet Gynecol Scand on October 17, 2012
Practical consideration of inserting intrauterine balloon during cesarean section for placenta previa. Acta Obstet Gynecol Scand (2013) 2.44
To tamponade or not to tamponade? Acta Obstet Gynecol Scand (2013) 2.10
Uterine compression sutures with intrauterine balloon tamponade. Acta Obstet Gynecol Scand (2013) 2.04
Double-balloon tamponade in the management of postpartum hemorrhage: a case series. Ther Clin Risk Manag (2014) 0.75
Uterine balloon tamponade in combination with topical administration of tranexamic Acid for management of postpartum hemorrhage. Case Rep Obstet Gynecol (2015) 0.75
Factors Contributing to Massive Blood Loss on Peripartum Hysterectomy for Abnormally Invasive Placenta: Who Bleeds More? Obstet Gynecol Int (2016) 0.75
Successful reduction of acute puerperal uterine inversion with the use of a bakri postpartum balloon. Case Rep Obstet Gynecol (2015) 0.75
Reply: Bakri balloon tamponade for postpartum hemorrhage. Acta Obstet Gynecol Scand (2013) 0.75
Does uterine gauze packing increase the risk of puerperal morbidity in the management of postpartum hemorrhage during caesarean section: a retrospective cohort study. Int J Clin Exp Med (2015) 0.75
Bakri balloon placement in the successful management of postpartum hemorrhage in a bicornuate uterus: A case report. Int J Surg Case Rep (2017) 0.75
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol (2002) 1.67
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol (2013) 1.58
Self-reported smoking habits and serum cotinine levels in women with placental abruption. Acta Obstet Gynecol Scand (2010) 1.58
Pelvic inflammatory disease. N Engl J Med (2015) 1.57
Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol (2009) 1.54
Cost-effectiveness of screening and treatment for bacterial vaginosis in early pregnancy among women at low risk for preterm birth. Acta Obstet Gynecol Scand (2004) 1.48
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial. Acta Obstet Gynecol Scand (2009) 1.43
Male fetal sex is associated with earlier onset of placental abruption. Acta Obstet Gynecol Scand (2010) 1.42
Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988-2011. Diabetologia (2015) 1.41
Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol (2007) 1.40
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS (2006) 1.32
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer (2011) 1.31
Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta Obstet Gynecol Scand (2011) 1.18
Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol (2003) 1.09
Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine (2006) 1.08
Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol (2013) 1.08
Clinical presentation and risk factors of placental abruption. Acta Obstet Gynecol Scand (2006) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer (2012) 1.04
Mutant CHUK and severe fetal encasement malformation. N Engl J Med (2010) 1.03
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer (2012) 1.01
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer (2010) 1.00
Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis (2008) 0.98
Vaccination against human papillomaviruses shows great promise. Lancet (2004) 0.97
The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod (2006) 0.97
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS (2008) 0.95
Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis (2010) 0.94
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health (2012) 0.91
Factors affecting matrix metalloproteinase-8 levels in the vaginal and cervical fluids in the first and second trimester of pregnancy. Hum Reprod (2009) 0.90
Transient urinary retention and chronic neuropathic pain associated with genital herpes simplex virus infection. Acta Obstet Gynecol Scand (2004) 0.89
The role of Chlamydia trachomatis infection in male infertility. Fertil Steril (2008) 0.89
Chlamydial heat shock protein 60--specific T cells in inflamed salpingeal tissue. Fertil Steril (2002) 0.89
Amniotic fluid oxidative and nitrosative stress biomarkers correlate with fetal chronic hypoxia in diabetic pregnancies. Neonatology (2012) 0.88
Chlamydia pneumoniae infection and the risk of female early-onset lung cancer. Int J Cancer (2003) 0.88
Nationwide increase of Chlamydia trachomatis infection in Finland: highest rise among adolescent women and men. Sex Transm Dis (2003) 0.88
The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol (2010) 0.88
Criteria for selective screening for Chlamydia trachomatis. Sex Transm Dis (2003) 0.87
High prevalence of sacrococcygeal teratoma in Finland - a nationwide population-based study. Acta Paediatr (2013) 0.87
Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes. Sex Transm Dis (2005) 0.86
Decreasing perinatal mortality in placental abruption. Acta Obstet Gynecol Scand (2012) 0.86
A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003. BMC Infect Dis (2008) 0.86
Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat Diagn (2007) 0.86
Prepregnancy risk factors for placental abruption. Acta Obstet Gynecol Scand (2006) 0.86
Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception (2006) 0.85
Long-term well-being after surgical or conservative treatment of severe vulvar vestibulitis. Acta Obstet Gynecol Scand (2012) 0.85
Placenta previa percreta left in situ - management by delayed hysterectomy: a case report. J Med Case Rep (2011) 0.84
Maternal deaths in Finland: focus on placental abruption. Acta Obstet Gynecol Scand (2009) 0.84
Cardiotocography and ST analysis for intrapartum fetal monitoring. Acta Obstet Gynecol Scand (2012) 0.83
Sound efficacy of prophylactic HPV vaccination: Basics and implications. Oncoimmunology (2012) 0.83
Interruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection. PLoS One (2012) 0.83
Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ (2010) 0.82
Decreasing incidence of placental abruption in Finland during 1980-2005. Acta Obstet Gynecol Scand (2012) 0.82
Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol (2014) 0.82
Age for HPV vaccination. Vaccine (2008) 0.82
Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int J Cancer (2013) 0.81
Amniotic fluid S100B protein and erythropoietin in pregnancies at risk for fetal hypoxia. Eur J Obstet Gynecol Reprod Biol (2008) 0.81
Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption. Prenat Diagn (2007) 0.81
Increased nuchal translucency and pregnancy outcome: a retrospective study of 1063 consecutive singleton pregnancies in a single referral institution. Prenat Diagn (2013) 0.80
Levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcome. Acta Obstet Gynecol Scand (2004) 0.80
Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding. Curr Opin Obstet Gynecol (2004) 0.80
Impact of HPV vaccination on young women's quality of life - a five year follow-up study. Eur J Contracept Reprod Health Care (2010) 0.80
Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med (2007) 0.79
Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women - a long-term follow-up study in a low-prevalence population. Int J STD AIDS (2006) 0.79
Periodontal disease and bacterial vaginosis increase the risk for adverse pregnancy outcome. Infect Dis Obstet Gynecol (2005) 0.79
Associations between three types of maternal bacterial infection and risk of leukemia in the offspring. Am J Epidemiol (2005) 0.79
Impact of HPV16/18 vaccination on quality of life: a pilot study. Eur J Contracept Reprod Health Care (2013) 0.78
Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome. J Matern Fetal Neonatal Med (2014) 0.78
Pelvic arterial embolization in severe obstetric hemorrhage. Acta Obstet Gynecol Scand (2014) 0.78
The significance of the second trimester sonographic soft markers in pregnancies after normal first trimester screening. Prenat Diagn (2013) 0.78
Amniotic fluid erythropoietin and neonatal outcome in pregnancies complicated by intrauterine growth restriction before 34 gestational weeks. Acta Obstet Gynecol Scand (2015) 0.78
Extralaryngeal HPV infections in male patients with adult-onset laryngeal papillomatosis. Eur Arch Otorhinolaryngol (2005) 0.78